What did @withmarianaa actually say?
The creator shared her experience using semaglutide (she calls it "semi-glutide") three months postpartum, at a Houston clinic called Clinic 45. She says she lost enough weight to return to her pre-pregnancy body in three months, without working out, and that she stopped the medication without side effects or rebound weight gain. She also addressed "Ozempic butt" and "Ozempic face," crediting her BBL history for why fat loss in her hips and glutes was actually a desired outcome rather than a problem.
To her credit, she repeatedly reminds viewers that "every body is different" and frames everything as personal experience rather than a prescription for others. That kind of disclaimer doesn't fully insulate 166K viewers from taking her results as a template, but it's at least honest framing.
Does the science back this up?
Some of it, yes. The weight loss results are real, but the timeline and the "no exercise needed" framing deserve scrutiny. Three months is fast, and the clinical trial data paints a more complicated picture than a smooth three-month arc.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks, not 12. The results that fast are possible, but they're not average. More importantly, that same trial found that one year after stopping semaglutide, participants regained roughly two-thirds of the weight they had lost (Wilding et al., 2022, Diabetes, Obesity and Metabolism). Her claim that she hasn't regained anything after three months off the drug is plausible in the short term, but three months post-injection is not enough time to declare victory on rebound.
On the exercise question: yes, semaglutide produces weight loss without mandatory exercise. But a 2023 study in Nature Medicine (Nadglowski et al.) confirmed that adding resistance training significantly reduces the proportion of weight lost as lean muscle mass versus fat, which matters for long-term metabolism. "No workout" is not the optimal path even if it works short-term.
What did they get right or wrong?
She got the hair loss framing mostly right. Postpartum telogen effluvium is a well-documented hormonal phenomenon, and semaglutide-associated hair loss (seen in roughly 3% of STEP trial participants) often overlaps with it temporally in new mothers. Blaming postpartum hormones first is defensible given her timeline.
She got the injection site guidance roughly right. Subcutaneous injection two to three inches from the navel is consistent with standard semaglutide administration instructions.
Where she falls short is the rebound framing. "It's been three months since my last injection. I didn't gain anything back" is presented as near-conclusive. It isn't. The pharmacological appetite suppression from semaglutide clears relatively quickly after stopping, but metabolic adaptation and behavioral drift tend to show up over six to twelve months, not ninety days. Telling viewers "now it's up to you to control" hunger is technically accurate but undersells how physiologically difficult that control becomes once the GLP-1 agonist effect is gone.
She also doesn't mention what dose she was on, what her monitoring looked like, or whether any labs were run. That's not a criticism of her, but it's information that matters when viewers consider replicating her experience.
What should you actually know?
If you're postpartum and considering semaglutide, there are real safety questions that this video doesn't touch. The American College of Obstetricians and Gynecologists has not issued formal guidance on GLP-1 use in the immediate postpartum period for non-diabetic patients. She confirmed she had stopped breastfeeding, which removes one major contraindication, but starting any weight-loss medication at three months postpartum warrants a conversation with an OB, not just a weight-loss clinic consultation.
The "Ozempic butt" phenomenon she addresses is real and involves loss of gluteal fat, not muscle. For patients without a BBL, this can be a significant aesthetic and structural concern. Her situation, where fat loss in that region was intentional, is genuinely different from the average patient's experience.
Finally, compounded semaglutide, which is what many weight-loss clinics were dispensing during the shortage period, is not equivalent to FDA-approved Wegovy or Ozempic. Dosing, purity, and sterility standards differ. She doesn't specify what form she received, and that gap matters for anyone trying to replicate her protocol.